SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as
being involved in formating the genetic and energy materials, supporting the structure of …

Improvements in sensor accuracy, greater convenience and ease of use, and expanding
reimbursement have led to growing adoption of continuous glucose monitoring (CGM) …

A substantial proportion of patients with adult-onset diabetes share features of both type 1
diabetes (T1D) and type 2 diabetes (T2D). These individuals, at diagnosis, clinically …

Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic β
cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite enhanced …

Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications
shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood …

In type 1 diabetes, insulin remains the mature therapeutic cornerstone; yet, the increasing
number of individuals developing type 1 diabetes (predominantly children and adolescents) …

Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all
current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become …

Euglycemic diabetic ketoacidosis (DKA) is an acute life-threatening metabolic emergency
characterized by ketoacidosis and relatively lower blood glucose (less than 11 mmol/L). The …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower
plasma glucose concentration by inhibiting Na+-glucose–coupled transport in the proximal …